The reasons for targeting EGFR in anticancer therapy are: the importance of EGFR signalling in the development of tumours; the association between EGFR overexpression and poor prognosis in many cancers; and the distinct mechanism of action of anti-EGFR approaches versus conventional methods. This evidence concerns the gene EGFR and cancer.